TABLE 3.
OFTT parameters in patients with NAFLD and controls grouped according to TCM6F2 rs58542926 C/T genotype (n = 120)
| Parameter | Controls | NAFLD | ||||
| TCM6F2 CC (n = 40) | TCM6F2 CT/TT (n = 20) | P | TCM6F2 CC (n = 40) | TCM6F2 CT/TT (n = 20) | P | |
| Fasting Tg (mg/dl) | 98 ± 11 | 86 ± 10 | 0.812 | 94 ± 15 | 85 ± 18 | 0.513 |
| IAUC Tg (mg/dl × h) | 141 ± 12 | 79 ± 10 | 0.001 | 525 ± 21b | 297 ± 20b | 0.00001 |
| Fasting NEFA (mmol/l) | 0.35 ± 0.23 | 0.47 ± 0.28 | 0.712 | 0.50 ± 0.29 | 0.63 ± 0.31 | 0.711 |
| IAUC NEFA (mmol/l × h) | 1.93 ± 0.27 | 0.82 ± 0.15 | 0.00009 | 5.24 ± 0.22b | 2.31 ± 0.28c | 0.0001 |
| Fasting VLDL1-Tg (mg/dl) | 42 ± 9 | 40 ± 10 | 0.812 | 52 ± 12 | 36 ± 10 | 0.201 |
| IAUC VLDL1-Tg (mg/dl × h) | 408 ± 29 | 123 ± 14 | 0.0001 | 922 ± 37b | 497 ± 31c | 0.00002 |
| Fasting VLDL2-Tg (mg/dl) | 30 ± 7 | 31 ± 7 | 0.813 | 36 ± 8 | 42 ± 9 | 0.312 |
| IAUC VLDL2-Tg (mg/dl × h) | 56 ± 10 | 89 ± 13 | 0.301 | 137 ± 14 | 131 ± 19 | 0.611 |
| Fasting VLDL1-Chol (mg/dl) | 10 ± 2 | 12 ± 2 | 0.812 | 14 ± 4 | 16 ± 4 | 0.713 |
| IAUC VLDL1-Chol (mg/dl × h) | 41 ± 4 | 92 ± 7 | 0.00009 | 97 ± 9c | 199 ± 11b | 0.000001 |
| Fasting VLDL2-Chol (mg/dl) | 15 ± 3 | 13 ± 3 | 0.712 | 18 ± 3 | 20 ± 4 | 0.611 |
| IAUC VLDL2-Chol (mg/dl × h) | 11 ± 1 | 32 ± 2 | 0.00009 | 37 ± 2c | 108 ± 4c | 0.000001 |
| Fasting LDL-C (mg/dl) | 103 ± 6 | 94 ± 6 | 0.131 | 107 ± 5 | 95 ± 10 | 0.210 |
| IAUC LDL-C (mg/dl × h) | −10 ± 2 | −24 ± 2 | 0.003 | −20 ± 3c,d | −51 ± 3b | 0.0001 |
| Fasting VLDL1 apoB48 (mg/dl) | 2.1 ± 0.4 | 2..0 ± 0.5 | 0.812 | 2.7 ± 0.9 | 2.4 ± 0.9 | 0.511 |
| IAUC VLDL1 apoB48 (mg/dl × h) | 4.5 ± 0.9 | 1.9 ± 0.5 | 0.0002 | 8.7 ± 1.4b | 4.3 ± 1.0c | 0.00001 |
| Fasting VLDL2 apoB48 (mg/dl) | 1.8 ± 0.4 | 1.5 ± 0.4 | 0.509 | 2.3 ± 0.6 | 2.1 ± 0.7 | 0.421 |
| IAUC VLDL2 apoB48 (mg/dl × h) | 1.5 ± 0.3 | 2.9 ± 0.5 | 0.008 | 1.6 ± 0.3 | 5.8 ± 0.6b | 0.0001 |
| Fasting VLDL1 apoB100 (mg/dl) | 3.7 ± 1.0 | 3.5 ± 1.1 | 0.712 | 4.5 ± 1.6 | 4.2 ± 1.7 | 0.913 |
| IAUC VLDL1 apoB100 (mg/dl × h) | 10.0 ± 1.5 | 3.9 ± 0.9 | 0.00009 | 22.4 ± 3.5b | 11.7 ± 2.9c | 0.00001 |
| Fasting VLDL2 apoB100 (mg/dl) | 3.7 ± 0.7 | 3.2 ± 0.9 | 0.802 | 5.2 ± 0.9 | 4.8 ± 1.1 | 0.611 |
| IAUC VLDL2 apoB100 (mg/dl × h) | 4.6 ± 0.9 | 8.3 ± 1.0 | 0.015 | 13.8 ± 1.9b | 24.5 ± 2.6b | 0.00001 |
| Fasting LDL C.D. (uA 234 nm/uA 200 nm × 100) | 7.3 ± 1.6 | 7.9 ± 1.8 | 0.902 | 7.5 ± 1.8 | 7.1 ± 1.6 | 0.616 |
| IAUC LDL C.D. (uA 234 nm/uA 200 nm × 100 × h) | 2.1 ± 0.1 | 0.8 ± 0.2 | 0.0009 | 15.1 ± 1.0b | 5.2 ± 1.2a | 0.00001 |
| Fasting HDL-C (mg/dl) | 54 ± 2 | 55 ± 2 | 0.210 | 52 ± 2 | 54 ± 2 | 0,212 |
| IAUC HDL-C (mg/dl × h) | −14 ± 2 | 2 ± 1 | 0.0001 | −56 ± 4b | −18 ± 2c | 0.00009 |
| Fasting GIP (pg/ml) | 18.8 ± 6.4 | 16.5 ± 6.1 | 0.712 | 22.1 ± 9.5 | 11.9 ± 5.2 | 0.211 |
| IAUC GIP (pg/ml × h) | 571.9 ± 18.5 | 266.4 ± 20.1 | 0.000008 | 703.9 ± 20.1b | 379.6 ± 24.4 | 0.000002 |
| Fasting adiponectin (ng/ml) | 8,631 ± 782 | 9,515 ± 812 | 0.412 | 6,161 ± 572 | 5,575 ± 650 | 0.713 |
| IAUC adiponectin (ng/ml × h) | 11,071 ± 912 | 12,916 ± 926 | 0.513 | 1,768 ± 246 | 1,536 ± 494 | 0.423 |
| Fasting resistin (ng/ml) | 3.4 ± 0.9 | 3.1 ± 1.0 | 0.912 | 3.8 ± 0.9 | 3.3 ± 0.9 | 0.301 |
| IAUC resistin (ng/ml × h) | 0.1 ± 0.1 | 1.5 ± 0.3 | 0.008 | 2.8 ± 1.1a | 6.4 ± 11.9b | 0.0000001 |
Oral fat load parameters of patients with NAFLD and controls according to TM6SF2 genotype. Data are presented as mean ± SEM. Statistically significant P values are in bold. C.D., conjugated dienes.
a
P < 0.05 versus controls.
b
P < 0.01 versus controls.
c
P < 0.05 versus controls bearing the same genotype.
d
P < 0.01 versus controls bearing the counterpart genotype.